Cell therapy (CAR-T) · Kills target cells, directed at HER2 (ERBB2) (ERBB2) · developed by Fate Therapeutics
FT825 is an off-the-shelf allogeneic CAR T-cell preparation derived from induced pluripotent stem cells, with a chimeric antigen receptor directed against HER2 (ERBB2). It targets and induces toxicity in HER2-expressing tumor cells and is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06241456 | Phase 1 | Advanced Solid Tumor | Recruiting | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →